All Editorials articles
-
OpinionCalifornia’s Proposition 38 reveals the promise and pitfalls of funding science via elections
Controversial ballot initiative means billions of dollars will likely go to research institute co-founded by one wealthy backer of Prop 38
-
OpinionAsking AI the right questions
As well as building better data to feed to artificial intelligence models, we need to be confident we can interrogate and verify their outputs
-
OpinionPeptides are getting a pass in the US. That could be a problem
Six popular ’wellness’ peptides, none of which have regulatory approval, will be distributed by compounding pharmacies
-
OpinionUK budget aims to promote ‘reindustrialisation’
Chancellor affirmed funding for previously introduced support measures, but competitiveness challenges remain
-
OpinionLearning the language of chemistry
Chemical structures embed vast amounts of information that needs translating for machines
-
OpinionUS atrazine cancer lawsuit revives hazard vs risk debate in pesticide regulation
Should firms have to issue cancer warnings in states that use different assessment criteria to national regulators?
-
ArticleA Nobel for chiral catalysts’ helping hand
This year’s laureates didn’t invent asymmetric synthesis, but filled in our understanding of how it works and how we can do it better
-
OpinionIneos temporarily closes UK acetyls plants
Owing to high high gas prices, the plants are uncompetitive, despite their high efficiency
-
OpinionFeeding AI’s appetite for data
Tapping companies’ archives makes for better predictions of how proteins bind drugs, but any data inputs need to be transparent and attributed
-
Opinion‘Molecular glues’ are sticking it to cancer
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
-
OpinionDeadly reminders of the importance of risk assessment
Serious incidents in two university labs highlight the importance of knowing what to do when things go wrong
-
OpinionArtificial intelligence or clever artifice?
It’s important to be realistic about what AI can, and can’t, achieve, across the chemistry enterprise
-
OpinionMessy megamergers
Rumoured merger between AstraZeneca and Bristol Myers Squibb has collapsed, and that’s probably a good thing
-
OpinionTrump threatens generic drug tariffs
Plan aims to encourage domestic US supplies, but will it work?
-
OpinionWhere does chemical recycling of plastics go from here?
US and EU plant closures highlight economic difficulties of scaling technology alongside associated policy and infrastructure
-
OpinionIt’s time for consensus on science’s place in government
The latest shake-up of UK science policy oversight brings uncertainty to a sector that needs stability to succeed
-
OpinionTrust is easily broken and hard to rebuild
Thermo Fisher needs to be open and honest about data manipulation to reassure researchers
-
OpinionIs industry getting more or less safe?
US figures suggest an increase in incidents involving serious injuries and fatalities in recent years
-
OpinionShould the EU stop exports of pesticides it has banned?
Agrochemicals including paraquat remain legal elsewhere, prompting questions over regulatory responsibility
-
OpinionGSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline